Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis
Episode 21 min 55s

Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.

Community discussion